Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: Nephros develops hemodiafiltration (HDF) products for End Stage Renal Disease (ESRD) and water filtration systems (Dual Stage Ultrafilter). The company operates in European and Canadian markets and holds government contracts for military water purification.
Key Financial Metrics
| Metric (in thousands) | Q1 2010 | Q1 2009 |
|---|---|---|
| Product Revenue | $989 | $631 |
| Gross Margin | $389 (39.3%) | $179 (28.4%) |
| Net Loss | $(528) | $(735) |
| Net Loss Per Share | $(0.01) | $(0.02) |
| Cash and Equivalents (End of Period) | $564 | $1,651 |
| Net Cash Used in Operating Activities | $(434) | $(660) |
| Total Assets | $2,289 | $2,652 |
| Total Liabilities | $877 | $694 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 57% to $989,000, driven by a $120,000 increase in Office of Naval Research (ONR) contract revenue, a $98,000 increase in U.S. Dual Stage Ultrafilter (DSU) sales, and a $140,000 increase in European MD filter sales.
- Improved Loss Position: Net loss narrowed by approximately $207,000 compared to the prior year, primarily due to revenue growth and a 50% reduction in depreciation expense as certain assets were fully depreciated.
- Expense Fluctuations: Selling, General, and Administrative (SG&A) expenses rose slightly to $807,000, impacted by a $55,000 severance accrual for the former CEO and higher legal fees, partially offset by reduced marketing and personnel costs.
- Liquidity Decline: Cash and cash equivalents decreased by $440,000 during the quarter, ending at $564,000. Inventory increased by $156,000, consuming cash.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management states that recurring losses and negative cash flows raise substantial doubt about the company's ability to continue as a going concern. The filing explicitly states that funds are projected to be depleted in the third quarter of 2010 without additional financing.
- Capital Needs: The company must raise additional funds through licensing, technology sales, or public/private equity offerings to sustain operations.
- Executive Changes: Ernest Elgin, III resigned as CEO and Board member on March 30, 2010. Paul Mieyal (Board member) serves as Acting CEO. A severance agreement with a maximum value of $55,000 has been accrued.
- Supply Chain Risk: The exclusive fiber supplier for the OLpur MDHDF filter series notified the company of its intent to terminate the supply agreement effective July 18, 2010. Negotiations for a new agreement are ongoing.
- Regulatory Status: The FDA is still reviewing the 510(k) application for the OLpur H2H module and MD 220 filter. The DSU received FDA approval for use in hemodialysis procedures in July 2009.
- Legal Proceedings: A claim regarding the cancellation of a 2008 Auction Rate Securities transaction was settled in March 2010 for $20,000 (accrued in 2009).
Investor Verification Checklist
- Runway: Verify the company's ability to secure financing before the projected Q3 2010 cash depletion.
- Supply Chain: Confirm the status of negotiations with the fiber supplier to ensure continuity of the MDHDF filter series production post-July 2010.
- Customer Concentration: Note that two customers (A and B) accounted for 88% of sales in Q1 2010 and 77% of accounts receivable.
- Regulatory Approval: Monitor the status of the pending FDA 510(k) application for the OLpur H2H and MD 220 products, which are critical for U.S. market expansion.
- Executive Stability: Assess the impact of the CEO resignation and the transition to an Acting CEO on strategic execution.